EditorialsNew tool to predict celiac disease on its way to the clinics☆
References (24)
Coeliac disease research and clinical practice: maintaining momentum into the twenty-first century
Baillieres Clin Gastroenterol
(1995)- et al.
Endomysial autoantibodies
- et al.
Autoantibodies to tissue transglutaminase as predictors of celiac disease
Gastroenterology
(1998) - et al.
Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease
Gastroenterology
(1998) - et al.
Mechanism of action of guinea pig liver transglutaminase. V. The hydrolysis reaction
J Biol Chem
(1968) - et al.
Fibroblasts and transforming growth factor β induce organization and differentiation of T84 human epithelial cells
Gastroenterology
(1996) - et al.
Celiac disease autoantibodies and tissue trans-glutaminase antibodies interfere similarly fibroblast induced epithelial cell (T84) differentiation (abstr)
Gastroenterology
(1998) Whither coeliac disease?
- et al.
Malignancy in coeliac disease—effect of a gluten free diet
Gut
(1989) - et al.
Endomysium antibodies in coeliac disease: an improved method
Gut
(1994)
Identification of tissue transglutaminase as the autoantigen of celiac disease
Nat Med
Gliadin-specific, HLA-DQ(α1*0501,β1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients
J Exp Med
Cited by (33)
Celiac disease
2005, Mucosal Immunology, Two-Volume SetTissue transglutaminase - The key player in celiac disease: A review
2004, Autoimmunity ReviewsRadioimmunoassay to detect antitransglutaminase autoantibodies is the most sensitive and specific screening method for celiac disease
2001, American Journal of GastroenterologyCitation Excerpt :Anti-tTGase autoantibodies represent the most recent serological marker proposed for screening of CD (28–30). These autoantibodies are particularly interesting from a speculative point of view because tTGase could catalyze the deamidation of gliadin peptides creating a negative charged residue better recognized by DQ2/DQ8 restricted gut-derived lymphocytes of CD patients (31). At present, two methods are available for tTGase antibody determination: an ELISA method, using guinea pig liver tTGase as antigen (19, 28–30, 32) and a RIA with a human recombinant tTGase (22, 33–35).
Human recombinant tissue transglutaminase ELISA: An innovative diagnostic assay for celiac disease
2000, American Journal of GastroenterologyCitation Excerpt :In this paper we described the development of an innovative human-based tTG ELISA, which allowed us to identify a total of 12 CD patients missed with the other two currently available noninvasive serological tests (seven patients missed by gp-tTG and five missed by AEA). These results support previously reported concerns regarding the use of nonhuman tTG as an alternative test to the AEA assay (10, 11), and may explain the small but consistent number of patients with CD who test negative by AEA. In our study, two of these patients were affected by IgA deficiency, a condition often associated with CD (17), and the remaining three had low specific anti–h-TG IgA antibodies (13%, 14%, and 20%).
- ☆
Address requests for reprints to: Ludvig M. Sollid, M.D., Institute of Transplantation Immunology, University of Oslo, Rikshospitalet, N-0027 Oslo, Norway. e-mail: [email protected]; fax: (47) 22 20-3693.